By understanding the molecular mechanisms regulating MDM2 splicing in response to damage and potentially in cancer we have paved the way for the development of novel splice modulation strategies for adjusting MDM2 levels in cancers with elevated MDM2-ALT1 and SRSF1 expression. This evidence concerns the gene MDM2 and cancer.